Warning: The NCBI web site requires JavaScript to function. more...
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A.
Arthritis Res Ther. 2009;11(6):R170. Epub 2009 Nov 12.
Related citations
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.
Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester GR, Hiepe F, Khanna D, Nikaï E, Coteur G, Schiff M.
Ann Rheum Dis. 2011 Jun;70(6):996-1002. Epub 2011 Mar 17.
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Keystone E, Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K.
Arthritis Rheum. 2008 Nov;58(11):3319-29. Erratum in: Arthritis Rheum. 2009 May;60(5):1249.
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF.
Arthritis Rheum. 2009 Nov 15;61(11):1592-600. Erratum in: Arthritis Rheum. 2010 Oct;62(10):1514.
Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P.
Rheumatology (Oxford). 2010 Oct;49(10):1900-10. Epub 2010 Jun 14.
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D.
Ann Rheum Dis. 2009 Jun;68(6):797-804. Epub 2008 Nov 17.
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V.
Ann Rheum Dis. 2009 Jun;68(6):805-11. Epub 2008 Nov 17.
Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.
Mease PJ.
Rheumatology (Oxford). 2011 Feb;50(2):261-70. Epub 2010 Sep 25. Review.
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijtens K, Keystone EC.
Arthritis Care Res (Hoboken). 2011 Jan;63(1):128-34. doi: 10.1002/acr.20331.
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, Mease PJ, Schiff MH, Coteur G, Davies O, Combe B.
J Rheumatol. 2011 Jun;38(6):990-6. Epub 2011 Mar 1.
Certolizumab pegol: in rheumatoid arthritis.
Duggan ST, Keam SJ.
BioDrugs. 2009;23(6):407-17. doi: 10.2165/11202800-000000000-00000. Review.
Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M.
Arthritis Rheum. 2011 Aug;63(8):2203-8. doi: 10.1002/art.30387.
Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.
J Rheumatol. 2008 Jan;35(1):20-30. Epub 2007 Nov 15.
Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN; CDP870 Crohn's Disease Study Group.
Int J Colorectal Dis. 2008 Mar;23(3):289-96. Epub 2007 Dec 11.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
Arthritis Rheum. 2004 May;50(5):1400-11.
Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S.
Am J Gastroenterol. 2009 Aug;104(8):1976-83. Epub 2009 May 26.
Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
Arthritis Rheum. 2001 Sep;44(9):1984-92.
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B; Leflunomide Rheumatoid Arthritis Investigators Groups.
J Rheumatol. 2005 Apr;32(4):590-601.
Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B.
J Rheumatol. 2011 May;38(5):835-45. Epub 2011 Jan 15.
RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
Ramiro S, van Tubergen AM, Landewé RB.
Expert Rev Clin Immunol. 2010 Sep;6(5):713-20. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on